-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Disease Progression
Exploring Lived Space as Experienced by Persons With Dementia (BMC Geriatrics)
Summary A systematic meta-synthesis concerning the broad topic of the experience(s) of space (whether physical, social or existential) on the part of persons living with dementia has identified four domains in the experience of “lived space”: (i) belonging (ii) meaningfulness … Continue reading →
Posted in For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), International, Management of Condition, Personalisation, Quick Insights, Systematic Reviews, Universal Interest
|
Tagged Autonomy, Autonomy and Choice, Autonomy and Safety, Autonomy and Self-Determination, BMC Geriatrics, Dementia Experiences, Dementia Progression (Experiences), Department of Nursing and Health Promotion: Oslo Metropolitan University, Department of Nursing and Health Sciences: University College of Southeast Norway, Department of Public Health and General Practice: Norwegian University of Science and Technology, Disease Progression, Existential Space, Experiences, Faculty of Health and Social Sciences: University College of Southeast Norway, Faculty of Health Sciences: Oslo Metropolitan University, Hermeneutic Approaches, Hermeneutics, Lived Space, Lived Space (Physical Social or Existential), Lived Space: Space as Experienced by Persons With Dementia, Meaningful Activity, Meaningful Activity and Occupation, Meaningful Activity in Care Homes / Nursing Homes, Meaningful Activity in the Community, Meaningful Occupation, Meaningful Relationships, Meaningfulness, National Institute of Public Health, Nolan's Six Senses (Security Continuity Belonging Purpose Fulfilment and Significance), Norway, Norwegian National Advisory Unit on Ageing and Health, Norwegian University of Science and Technology, Oslo Metropolitan University, Participant Lived Experiences, Patient and Carer Experiences, Patient Autonomy, Patient Experiences, Personal Security, Physical Space, Progression of Mild Cognitive Impairment to Dementia, Qualitative Research, Quality Statement 1: Participation in Meaningful Activity, Respect for Autonomy, Safety and Security, Security, Security: Six Senses, Senses Framework (Security; Belonging; Continuity; Purpose; Achievement; Significance), Six Senses (Security Belonging Continuity Purpose Achievement Significance), Social Space, Systematic Reviews and Meta-Analyses, University College of Southeast Norway
|
Leave a comment
Progression of Neurological Diseases Presaged By Hidden Alterations in Artistic Style? (BBC News / Neuropsychology)
Summary Psychological researchers performed detailed mathematical analysis (“fractal analysis”) of barely perceptible changes to the brushstrokes used by artists, some of whom later developed neurological diseases. Analysis of hidden patterns of change in the fractal dimension of paintings reveals that … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest
|
Tagged Alterations to Artistic Style, and Wear Valleys NHS Trust, Artworks, BBC Health News, Department of Computer Science: Maynooth University, Department of Psychology: University of Liverpool, Disease Progression, Fine Art, Fine Motor Control, Fractal Analysis of Artistic Brushstrokes, Fractal Analysis of Neurological Changes (In Artists), Fractal Analysis of Paintings, Ireland, Maynooth University, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuropsychology (Journal), Progression of Neurological Diseases, Pyschology of Art, Symptoms and Progression of Dementia, Tees Esk, University of Liverpool, Variations in Motor Control
|
Leave a comment
World Alzheimer’s Day (BBC News / ARUK / OHE / NHS Choices)
Summary To mark World Alzheimer’s Day, life-expectancy and dementia incidence statistics, commissioned from the Office of Health Economics, have been used to arrive at the projection that perhaps one in three people born in the UK this year could develop … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Commissioning, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Management of Condition, Models of Dementia Care, NHS Digital (Previously NHS Choices), Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Ageing Population, Ageing Society, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Behind the Headlines, CFAS I Study, Cognitive Functioning and Ageing Study (CFAS), Costs of Dementia in UK, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Dementia Innovation, Dementia Research, Dementia Research Champions Group, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Epidemiology, Estimation of Future Cases of Dementia: From Males / Females Born in 2015, Forecasting Life Expectancy, Gender (Sex), Gender Differences in Diagnosis Rates, Incidence Studies, Life Expectancy, Life Table Data, Life Tables, National Life Tables, Office of Health Economics (OHE), OHE Consulting, OHE: Office of Health Economics, Prevalence, Prevalence of Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Trajectory of Dementia in the UK
|
Leave a comment
New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)
Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Association International Conference (Washington, Alzheimer’s Association International Conference® (AAIC®) 2015, Alzheimer’s Research UK (ARUK), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, ARUK: Alzheimer’s Research UK, BBC Health News, Big Pharma, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Eli Lilly, EXPEDITION Studies, β-amyloid, July 2015), Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody
|
Leave a comment
Defeat Dementia Report (Alzheimer’s Research UK / OHE / BBC News)
Summary Alzheimer’s Research UK (ARUK) released their “Defeat Dementia: the evidence and a vision for action” last week to coincide with the Global Dementia Legacy Event and the launch of their “Defeat Dementia” campaign. This report draws on analyses from … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Age of Dementia Onset, Alzheimer’s Disease: Prevalence, ARUK: Alzheimer’s Research UK, BBC Health News, Burden of Alzheimer’s Disease, Burden of Dementia, Burden on Caregivers, Carer Burden in Dementia, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Economic Analyses, Economic Case for Prevention, Economic Modelling, Epidemiology, Epidemiology and Statistics, Family Carers, Global Dementia Legacy Event, Informal Carers, Institute for Public Policy Research (ippr), ippr: Institute for Public Policy Research, Office of Health Economics (OHE), Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Social Epidemiology, University College London, Unpaid Caregivers (Carers), Unpaid Carers, Wider Societal Burden
|
Leave a comment
Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)
Summary Accurate and sensitive tools are required for the early detection / diagnosis of Alzheimer’s Disease, particularly to assist research. Alzheimer’s Disease clinical trials make increasing use of biomarkers, particularly neuroimaging markers and cerebrospinal fluid (CSF) biomarkers obtained via invasive … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Quick Insights
|
Tagged Aβ42, Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort, Alzheimer’s Disease Clinical Trials, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Argentina, Australia, Autonomous Systems Laboratory: Universidad Politécnica de Madrid, Avid’s AV-45 (Florbetapir), Belgium, Beta-Amyloid, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomedical Engineering Laboratory: Okayama University, BM List of AD Biomarkers, BM=(w o τ aβ hc fc tac), Canada, Cerebrospinal Fluid (CSF), Chile, Clearance of Amyloid Beta Protein, Compliance with Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Computed Tomography (CT), CSF, CSF Aβ, CSF Aβ(1-42), CSF Tau, Default-Mode Network (DMN), Dementia Research, Denmark, Disease Progression, Finland, Fludeoxyglucose FDG PET, Flutemetamol (18F), fMRI, France, Frontiers in Aging Neuroscience, Functional Connectivity, Functional Magnetic Resonance Imaging (fMRI), GE’s Flutametamol, Germany, Global Alzheimer’s Association Interactive Network (GAAIN), Hippocampus, Hyperphosphorylated Tau, India, Israel, Italy, β-amyloid, β-Amyloid 1-42 (Aβ42), Japan, Lumbar Puncture Compliance, Lumbar Punctures, Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Measurement of Treatment Effects, Mexico, Morphometric Analysis, Network-Based Biomarkers, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, o (Orientation), Okayama University, Poland, Positron Emission Tomography (PET), Quintiles, Resting-State fMRI (R-fMRI), South Africa, Spain, Sweden, Tactile Biomarker (tac), Taiwan, Tau Pathology, Tau Protein, Universidad Politécnica de Madrid, USA, Volumetric MRI, w (Word Recognition)
|
Leave a comment
